20. In regulation 45(1)(f)(i), [F1for “or any equivalent provisions in any EEA State other than the United Kingdom” substitute “or, in the case of an investigational medicinal product manufactured or assembled in Northern Ireland, any equivalent provisions in any EEA State”.] .
Textual Amendments
F1Words in reg. 20 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 1 para. 6
Commencement Information
I1Reg. 20 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1